Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niklas Ekman

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Expert Review of Clinical Pharmacology|August 22, 2015
Biosimilar regulation in the EUPekka Kurki, Niklas Ekman
The Journal of Organic Chemistry|May 31, 1996
Synthesis of Optically Active endo,endo Bicyclo[2.2.2]octane-2,5-diol, Bicyclo[2.2.2]octane-2,5-dione, and Related CompoundsFredrik Almqvist, Niklas Ekman, Torbjörn Frejd
Clinical Pharmacology and Therapeutics|December 22, 2022
A Data Driven Approach to Support Tailored Clinical Programs for Biosimilar Monoclonal AntibodiesElena Guillen, Niklas Ekman, Sean Barry, et al.
The Journal of Biological Chemistry|July 2, 2003
p130Cas Couples the tyrosine kinase Bmx/Etk with regulation of the actin cytoskeleton and cell migrationYama A Abassi, Marko Rehn, Niklas Ekman, et al.
Molecular Biology of the Cell|July 2, 2004
Bmx tyrosine kinase transgene induces skin hyperplasia, inflammatory angiogenesis, and accelerated wound healingKarri Paavonen, Niklas Ekman, Maria Wirzenius, et al.
The Journal of Biological Chemistry|October 9, 2003
Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathwayRong Zhang, Yingqian Xu, Niklas Ekman, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 21, 2022
Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical ExperiencePekka Kurki, Hye-Na Kang, Niklas Ekman, et al.
Biochimica Et Biophysica Acta|October 3, 2006
The LKB1 tumor suppressor kinase in human diseasePekka Katajisto, Tea Vallenius, Kari Vaahtomeri, et al.
Development (Cambridge, England)|June 10, 2008
LKB1 in endothelial cells is required for angiogenesis and TGFbeta-mediated vascular smooth muscle cell recruitmentAnou Londesborough, Kari Vaahtomeri, Marianne Tiainen, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 13, 2023
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?Nadine Kirsch-Stefan, Elena Guillen, Niklas Ekman, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Expert Review of Clinical Pharmacology|August 22, 2015
Biosimilar regulation in the EUPekka Kurki, Niklas Ekman
The Journal of Organic Chemistry|May 31, 1996
Synthesis of Optically Active endo,endo Bicyclo[2.2.2]octane-2,5-diol, Bicyclo[2.2.2]octane-2,5-dione, and Related CompoundsFredrik Almqvist, Niklas Ekman, Torbjörn Frejd
Clinical Pharmacology and Therapeutics|December 22, 2022
A Data Driven Approach to Support Tailored Clinical Programs for Biosimilar Monoclonal AntibodiesElena Guillen, Niklas Ekman, Sean Barry, et al.
The Journal of Biological Chemistry|July 2, 2003
p130Cas Couples the tyrosine kinase Bmx/Etk with regulation of the actin cytoskeleton and cell migrationYama A Abassi, Marko Rehn, Niklas Ekman, et al.
Molecular Biology of the Cell|July 2, 2004
Bmx tyrosine kinase transgene induces skin hyperplasia, inflammatory angiogenesis, and accelerated wound healingKarri Paavonen, Niklas Ekman, Maria Wirzenius, et al.
The Journal of Biological Chemistry|October 9, 2003
Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathwayRong Zhang, Yingqian Xu, Niklas Ekman, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 21, 2022
Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical ExperiencePekka Kurki, Hye-Na Kang, Niklas Ekman, et al.
Biochimica Et Biophysica Acta|October 3, 2006
The LKB1 tumor suppressor kinase in human diseasePekka Katajisto, Tea Vallenius, Kari Vaahtomeri, et al.
Development (Cambridge, England)|June 10, 2008
LKB1 in endothelial cells is required for angiogenesis and TGFbeta-mediated vascular smooth muscle cell recruitmentAnou Londesborough, Kari Vaahtomeri, Marianne Tiainen, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 13, 2023
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?Nadine Kirsch-Stefan, Elena Guillen, Niklas Ekman, et al.
Pageof 2